The aim of this project is to develop Cardiomyopathy syndrome (CMS) resistant Atlantic salmon using next-generation gene editing technologies and design breeding schemes that take advantage of edited genes.

Specific objectives:

  • To identify potential genes and causative mutation affecting CMS resistance in Atlantic salmon.
  • To develop efficient CRISPR/Cas9 constructs that will result in CMS resistant Atlantic salmon.
  • Design breeding schemes to deliver edited genes from their first creation to large-scale commercial production.
  • To determine the ethical, social and legal implications of developing CMS resistant Atlantic salmon using gene editing through an RRI approach.


FNI's task involves examining the evolving legal and institutional frameworks that regulate breeding in aquaculture, as well as the impact of technological developments. Gene editing techniques open new legal questions for both the cluster of rules regulating rights to genetic material and opens new possibilities in respect of using patents to secure exclusive rights.

 

Time frame: 2019-2022
 

FNI PROJECT LEADER

PARTNERS
FUNDING
  • Research Council of Norway